Research Comparison
Adipotide (Prohibitin-TP01) vs Survodutide (BI 456906)
A side-by-side research comparison of Adipotide (Prohibitin-TP01) and Survodutide (BI 456906) drawn from Cobalt Peptides' peptide database records.
Adipotide (Prohibitin-TP01)
Adipotide (Prohibitin-TP01) is a chimeric peptidomimetic combining a targeting sequence (CKGGRAKDC) that binds prohibitin and annexin A2 on adipose endothelial cells with a pro-apoptotic mitochondrial-disrupting motif, D-(KLAKLAK)2. It was investigated in preclinical models of adiposity. Its development was HALTED following early clinical investigation because of renal safety findings — reversible proximal tubule toxicity observed in primate studies. It is not an approved medicine and is supplied strictly as a research compound for laboratory use.
Survodutide (BI 456906)
Survodutide (BI 456906) is an investigational dual glucagon receptor and GLP-1 receptor agonist. It is a 29-amino acid peptide with C18 fatty acid acylation, a modification that extends its duration of action and supports once-weekly administration in study protocols. Its dual mechanism engages both receptors rather than one, and is the subject of ongoing published research. Survodutide is not an approved medicine. Supplied strictly as a research compound for laboratory use.